{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:01:04Z","timestamp":1780488064019,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":418,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.cmi.2022.10.015","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T12:52:04Z","timestamp":1666270324000},"page":"372-378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial"],"prefix":"10.1016","volume":"29","author":[{"given":"Theodoros","family":"Karampitsakos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ourania","family":"Papaioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Tsiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthaios","family":"Katsaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Katsimpris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas P.","family":"Kalogeropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elli","family":"Malakounidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Zarkadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Tsirikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Georgiopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilina","family":"Sotiropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Electra","family":"Koulousousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charikleia","family":"Chourpiliadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Matsioulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lagadinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios","family":"Sampsonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Akinosoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markos","family":"Marangos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argyris","family":"Tzouvelekis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2022.10.015_bib1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.10.015_bib2","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.10.015_bib3","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.10.015_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with Covid-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.10.015_bib5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12931-021-01914-6","article-title":"Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study","volume":"22","author":"Karampitsakos","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.cmi.2022.10.015_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(22)01109-6","article-title":"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.10.015_bib7","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.10.015_bib8","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2022.10.015_bib9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.reuma.2020.10.009","article-title":"Experience with the use of baricitinib and tocilizumab monotherapy or combined, in patients with interstitial pneumonia secondary to coronavirus COVID19: a real-world study","volume":"18","author":"Rosas","year":"2022","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.cmi.2022.10.015_bib10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3390\/medicina58040513","article-title":"Comparative efficacy of tocilizumab and baricitinib administration in COVID-19 treatment: A retrospective cohort study","volume":"58","author":"Kojima","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.cmi.2022.10.015_bib11","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1186\/s12879-021-06536-3","article-title":"Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients","volume":"21","author":"Dessie","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2022.10.015_bib12","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A\u00a0minimal common outcome measure set for COVID-19 clinical research","volume":"20","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.10.015_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-044480","article-title":"Testing for non-inferior mortality: a systematic review of non-inferiority margin sizes and trial characteristics","volume":"11","author":"Pong","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.cmi.2022.10.015_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12874-018-0500-3","article-title":"Bias due to censoring of deaths when calculating extra length of stay for patients acquiring a hospital infection","volume":"18","author":"Rahman","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.cmi.2022.10.015_bib15","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(22)00088-1","article-title":"Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial","volume":"10","author":"Wolfe","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2022.10.015_bib16","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.10.015_bib17","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S2213-2600(21)00358-1","article-title":"Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial","volume":"9","author":"Kalil","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2022.10.015_bib18","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.10.015_bib19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(21)00081-3","article-title":"Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial","volume":"9","author":"Soin","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2022.10.015_bib20","doi-asserted-by":"crossref","first-page":"n84","DOI":"10.1136\/bmj.n84","article-title":"Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial","volume":"372","author":"Veiga","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2022.10.015_bib21","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe Covid-19 pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.10.015_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial","volume":"181","author":"Hermine","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cmi.2022.10.015_bib23","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19","volume":"384","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.10.015_bib24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cmi.2022.10.015_bib25","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.cmi.2022.02.027","article-title":"Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM\u2014a prospective, randomized, single-centre, open-label study","volume":"28","author":"Broman","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2022.10.015_bib26","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00803-2022","article-title":"Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline","volume":"60","author":"Roche","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2022.10.015_bib27","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02523-2021","article-title":"Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group","volume":"60","author":"Hermine","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2022.10.015_bib28","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-2600(21)00139-9","article-title":"Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context","volume":"9","author":"Angriman","year":"2021","journal-title":"Lancet Respir Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22005298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22005298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:33:32Z","timestamp":1761118412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X22005298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1198743X22005298"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2022.10.015","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.06.13.22276211","asserted-by":"object"}]},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2022.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}